Menu Close

Controversial Alzheimer’s drug should not be approved out of desperation, warn Aussie experts

Aducanumab, a controversial Alzheimer’s disease medication with “questionable efficacy,” is under review by the Therapeutic Goods Administration, but authors of a Perspective published today by the Medical Journal of Australia say “science, not desperation” should guide the process.